Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00005878 |
Recruitment Status :
Completed
First Posted : January 27, 2003
Last Update Posted : October 13, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing cancer in patients with Barrett's esophagus.
PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing cancer in patients who have Barrett's esophagus.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Esophageal Cancer | Drug: celecoxib | Phase 2 |
OBJECTIVES:
- Determine the safety and efficacy of celecoxib for regression of Barrett's dysplasia in patients with low or high-grade dysplasia of the esophagus.
OUTLINE: This is a randomized, parallel, double-blind, placebo-controlled, multicenter study. Patients are stratified according to center and grade of dysplasia at baseline (low vs high). Patients are randomized to one of two treatment arms.
- Arm I: Patients receive oral celecoxib twice daily for 48-96 weeks.
- Arm II: Patients receive oral placebo as in arm I. Treatment continues in both arms in the absence of unacceptable toxicity or development of adenocarcinoma of the esophagus or cancer at other sites.
Patients are followed at 12 weeks.
PROJECTED ACCRUAL: A total of 200 patients (100 per arm) will be accrued for this study.
Study Type : | Interventional (Clinical Trial) |
Allocation: | Randomized |
Masking: | Double |
Primary Purpose: | Prevention |
Official Title: | Chemoprevention for Barrett's Esophagus Trial (CBET) |
Study Start Date : | July 2000 |
Actual Primary Completion Date : | September 2005 |
Actual Study Completion Date : | September 2005 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 120 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
-
Histologically confirmed Barrett's dysplasia with specific information on the location (level) of the highest grade of dysplasia based on biopsy from baseline endoscopy
- Short segment Barrett's esophagus must be sufficient area to allow for biopsy without complete resection
- No presence of reflux esophagitis grades 2-4
- No history of confirmed invasive carcinoma of the esophagus
- No diagnosis of esophageal, gastric, pyloric channel, or duodenal ulceration of 1 cm or more in diameter within the past 30 days
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- ECOG 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Hemoglobin at least 9 g/dL
- Platelet count greater than 125,000/mm^3
- WBC greater than 3,000/mm^3
- No significant bleeding disorder
- No other abnormal hematopoietic laboratory test result that would preclude study
Hepatic:
- PT/PTT no greater than 1.5 times upper limit of normal (ULN)
- AST/ALT less than 1.5 times ULN
- Alkaline phosphatase less than 1.5 times ULN
- No chronic or acute hepatic disorder
- No abnormal hepatic laboratory test result that would preclude study
Renal:
- Creatinine no greater than 1.5 times ULN
- No chronic or acute renal disorder
- No other abnormal renal laboratory test result that would preclude study
Other:
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No prior or concurrent active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)
- No other prior or concurrent curatively treated malignancy with a survival prognosis of less than 5 years
- No hypersensitivity or adverse reaction to COX-2 inhibitors (e.g., celecoxib), sulfonamides, salicylates, or NSAIDs
- No other significant medical, psychological, or psychosocial condition that would preclude study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- Not specified
Endocrine therapy:
- At least 6 months since prior regular (at least 2 weeks duration) oral or intravenous corticosteroids
- At least 6 months since prior regular (at least 4 weeks duration) inhaled corticosteroids
- No concurrent regular oral or intravenous corticosteroids
- No concurrent regular inhaled corticosteroids
- Concurrent corticosteroid nasal spray allowed
Radiotherapy:
- At least 12 weeks since prior radiotherapy to the chest or upper abdomen
Surgery:
- At least 3 months since prior surgery to the esophagus or stomach except hiatal hernia repair, fundoplication, vagotomy, or pyloroplasty
- No prior complete mucosal resection using any technique
- No concurrent resection of high-grade nodule
Other:
- At least 30 days since prior chronic (at least 3 times a week for greater than 2 weeks) aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs) (i.e., greater than 100 mg/day)
- No prior complete mucosal ablation using any technique
- No prior treatment on this study
- At least 30 days since prior investigational medication including shingles vaccine
- No concurrent chronic NSAIDs or COX-2 inhibitors except low-dose aspirin (i.e., no greater than 100 mg/day)
- No concurrent anticoagulants (e.g., heparin or warfarin)
- No other concurrent investigational medication

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005878
United States, Arizona | |
Veterans Affairs Medical Center - Tucson | |
Tucson, Arizona, United States, 85723 | |
United States, California | |
Jonsson Comprehensive Cancer Center, UCLA | |
Los Angeles, California, United States, 90095-1781 | |
United States, Illinois | |
Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital) | |
Hines, Illinois, United States, 60141 | |
United States, Maryland | |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
Baltimore, Maryland, United States, 21231-2410 | |
United States, Minnesota | |
Mayo Clinic Cancer Center | |
Rochester, Minnesota, United States, 55905 | |
United States, New York | |
Herbert Irving Comprehensive Cancer Center | |
New York, New York, United States, 10032 | |
United States, Ohio | |
Ireland Cancer Center | |
Cleveland, Ohio, United States, 44106 | |
United States, Oregon | |
Veterans Affairs Medical Center - Portland | |
Portland, Oregon, United States, 97207 |
Study Chair: | Arlene A. Forastiere, MD | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Responsible Party: | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
ClinicalTrials.gov Identifier: | NCT00005878 |
Other Study ID Numbers: |
JHOC-J9932, CDR0000067917 P30CA006973 ( U.S. NIH Grant/Contract ) JHOC-J9932 JHOC-99061108 NCI-P00-0145 |
First Posted: | January 27, 2003 Key Record Dates |
Last Update Posted: | October 13, 2016 |
Last Verified: | October 2016 |
esophageal cancer |
Esophageal Neoplasms Barrett Esophagus Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Head and Neck Neoplasms Digestive System Diseases Esophageal Diseases Gastrointestinal Diseases Precancerous Conditions Celecoxib |
Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Cyclooxygenase 2 Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |